The effects of chemotherapeutic drugs on PD-L1 gene expression in breast cancer cell lines.
Breast cancer cell lines
Docetaxel
Doxorubicin
PD-L1
Paclitaxel
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
23 Oct 2021
23 Oct 2021
Historique:
received:
02
07
2021
accepted:
24
07
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
8
2
2022
Statut:
epublish
Résumé
Breast cancer is the most common cancer among women in terms of prevalence and mortality, and chemotherapy is one of the most effective treatments at higher stages. However, resistance to chemotherapy is the main obstacle in the treatment of this cancer. Accumulated evidence identified the PD-L1 protein as an essential protein in the development of different cancers. Abnormal expression of this protein in various tumor cells is linked to cancer development and inhibiting the function of immune cells, which correlated with reduced beneficial effects of chemotherapy drugs. In the present study, the effects of common chemotherapy drugs including doxorubicin, paclitaxel, and docetaxel on the expression of the PD-L1 gene were investigated by qRT-PCR before and after the treatment with these drugs in MD231, MD468, SKBR3 breast cancer cell lines. Also, the MTT test was applied to examine the effects of drugs on the growth and proliferation of cancer cells considering PD-L1 expression. The expression of the PD-L1 gene increased after 24 and 48 h of treatment with chemotherapy drugs. The obtained results indicate the enhancing effects of chemotherapy drugs on PD-L1 gene expression, which have a suppressive effect on the immune system against breast cancer. The use of these drugs as the first line of chemotherapy in triple-negative breast cancer is not recommended. However, there is still a need for further experimental and clinical research on the exact effects of these drugs on undesired immune cells exhaustion in breast cancer therapy.
Identifiants
pubmed: 34687372
doi: 10.1007/s12032-021-01556-0
pii: 10.1007/s12032-021-01556-0
doi:
Substances chimiques
Antineoplastic Agents
0
B7-H1 Antigen
0
CD274 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
147Subventions
Organisme : Tabriz University of Medical Sciences
ID : 62280
Informations de copyright
© 2021. Springer Science+Business Media, LLC, part of Springer Nature.
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. Cancer. 2007;109:1721–8.
doi: 10.1002/cncr.22618
Dias K, Dvorkin-Gheva A, Hallett RM, Wu Y, Hassell J, Pond GR, et al. Claudin-low breast cancer; clinical & pathological characteristics. PLoS ONE. 2017;12:e0168669.
doi: 10.1371/journal.pone.0168669
Makki J. Diversity of breast carcinoma: histological subtypes and clinical relevance. Clin Med Insights Pathol. 2015. https://doi.org/10.4137/CPath.S31563 .
doi: 10.4137/CPath.S31563
pubmed: 26740749
pmcid: 4689326
Schnitt SJ. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Mod Pathol. 2010;23:S60–4.
doi: 10.1038/modpathol.2010.33
Derakhshani A, Rezaei Z, Safarpour H, Sabri M, Mir A, Sanati MA, et al. Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy. J Cell Physiol. 2020;235:3142–56.
doi: 10.1002/jcp.29216
Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JGM, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008;68:3108–14.
doi: 10.1158/0008-5472.CAN-07-5644
Dong G, Wang D, Liang X, Gao H, Wang L, Yu X, et al. Factors related to survival rates for breast cancer patients. Int J Clin Exp Med. 2014;7:3719.
pubmed: 25419424
pmcid: 4238527
Dastmalchi N, Safaralizadeh R, Baradaran B, Hosseinpourfeizi M, Baghbanzadeh A. An update review of deregulated tumor suppressive microRNAs and their contribution in various molecular subtypes of breast cancer. Gene. 2020;729:144301.
doi: 10.1016/j.gene.2019.144301
Soliman H, Khalil F, Antonia S. PD-L1 expression is increased in a subset of basal type breast cancer cells. PLoS ONE. 2014;9:e88557.
doi: 10.1371/journal.pone.0088557
Zheng Y, Fang Y, Li J. PD-L1 expression levels on tumor cells affect their immunosuppressive activity. Oncol Lett. 2019;18(5):5399–407.
pubmed: 31612048
pmcid: 6781757
Sabatier R, Finetti P, Mamessier E, Adelaide J, Chaffanet M, Ali HR, et al. Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget. 2015;6:5449–64.
doi: 10.18632/oncotarget.3216
Howard JH, Bland KI. Current management and treatment strategies for breast cancer. Curr Opin Obstet Gynecol. 2012;24:44–8.
doi: 10.1097/GCO.0b013e32834da4b1
Hassan MSU. Chemotherapy for breast cancer (review). Oncol Rep. 2010;24:1121–31.
doi: 10.3892/or_00000963
Martin AM, Nirschl TR, Nirschl CJ, Francica BJ, Kochel CM, van Bokhoven A, et al. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer Prostatic Dis. 2015;18:325–32.
doi: 10.1038/pcan.2015.39
Ng HY, Li J, Tao L, Lam AK-Y, Chan KW, Ko JMY, et al. Chemotherapeutic treatments increase PD-L1 expression in esophageal squamous cell carcinoma through EGFR/ERK activation. Transl Oncol. 2018;11:1323–33.
doi: 10.1016/j.tranon.2018.08.005
Ghebeh H, Mohammed S, Al-Omair A, Qattant A, Lehe C, Al-Qudaihi G, et al. The B7–H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 2006;8:190–8.
doi: 10.1593/neo.05733
Lotfinejad P, Kazemi T, Safaei S, Amini M, Roshani asl E, Baghbani E, et al. PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines. Biomed Pharmacother. 2021;138:111436.
doi: 10.1016/j.biopha.2021.111436
Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2:361–70.
doi: 10.1158/2326-6066.CIR-13-0127
Bailly C, Thuru X, Quesnel B. Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times. NAR Cancer. 2020;2:zcaa002.
doi: 10.1093/narcan/zcaa002
Yang M, Liu P, Wang K, Glorieux C, Hu Y, Wen S, et al. Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligand 1 expression in bone marrow stromal cells. Mol Oncol. 2017;11:358–72.
doi: 10.1002/1878-0261.12032
Zhang P, Su D-M, Liang M, Fu J. Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis. Mol Immunol. 2008;45:1470–6.
doi: 10.1016/j.molimm.2007.08.013
Funaki S, Shintani Y, Kawamura T, Kanzaki R, Minami M, Okumura M. Chemotherapy enhances programmed cell death 1/ligand 1 expression via TGF-β induced epithelial mesenchymal transition in non-small cell lung cancer. Oncol Rep. 2017;38:2277–84.
doi: 10.3892/or.2017.5894
Gu Z, Wang Q, Shi Y, Huang Y, Zhang J, Zhang X, et al. Nanotechnology-mediated immunochemotherapy combined with docetaxel and PD-L1 antibody increase therapeutic effects and decrease systemic toxicity. J Control Release. 2018;286:369–80.
doi: 10.1016/j.jconrel.2018.08.011
Nounou MI, ElAmrawy F, Ahmed N, Abdelraouf K, Goda S, Syed-Sha-Qhattal H. Breast cancer: conventional diagnosis and treatment modalities and recent patents and technologies. Breast Cancer Basic Clin Res. 2015;9(2):17–34.
Lotfinejad P, Kazemi T, Mokhtarzadeh A, Shanehbandi D, Jadidi Niaragh F, Safaei S, et al. PD-1/PD-L1 axis importance and tumor microenvironment immune cells. Life Sci. 2020;259:118297.
doi: 10.1016/j.lfs.2020.118297